Share:
Ark Funds hosted an investor webinar Tuesday, sharing ideas on several industries and portfolio components, including a discussion on some names in the genomics space.
Ark Funds On Genomics: Ark Funds is well-known for its bullish thesis on the genomics market. The company has the Ark Genomic Revolution ETF (BATS: ARKG), an ETF devoted to the growth of the segment.
Exact Sciences (NASDAQ: EXAS) was highlighted by Ark Funds analyst Simon Barnett.
The company has made a series of acquisitions that could help the company’s position in the market, he said.
“Incorporating it all together, Exact can broaden out their portfolio [and] determine market share.”
5 Stocks To Watch For February 17, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Exact Sciences (NASDAQ: EXAS) shares are trading lower on Wednesday after the company reported its fourth-quarter earnings.
The company also entered into an .
UK variant of coronavirus confirmed to be in Arizona, health officials confirm
Its scientific name is B.1.1.7., but it is also known as the UK variant of the COVID-19 virus.
By: abc15.com staff, Scripps National
Posted at 11:24 AM, Jan 29, 2021
and last updated 2021-01-30 19:17:10-05
PHOENIX â A variant of coronavirus first spotted in the United Kingdom has made its way to Arizona, health officials confirmed late Friday.
Sources initially alerted ABC15 Friday morning that the variant, which has been shown to spread more easily from person to person, had been detected in our state and that officials were in contact with the Centers for Disease Control and Prevention about its arrival.
Study offers a differentiated patient-specific solution in minimal residual disease testing
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
Analysis of DNA shed into a patient s blood stream can provide a noninvasive means of detecting the presence of a tumor. Patients who have undergone initial treatment may only have small amounts of tumor DNA in their blood, which can be difficult to detect with conventional technology. TARDIS was developed to be highly sensitive and customizable for each patient, including those with only a trace amount of tumor remaining following surgery or other localized treat